中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

2013 No. 9

Display Method:
Editorial
Acute- on- chronic liver failure: from pathophysiology to clinical practice
Li JunFeng, Duan ZhongPing
2013, 29(9): 641-644. DOI: 10.3969/j.issn.1001-5256.2013.09.001
Abstract:
Acute- on- chronic liver failure ( ACLF) is a clinical syndrome with rapid liver function decompensation as a result of chronic liver disease. As a clinical entity characterized by rapid progression, requirement for multiple organ support therapy, and a short- and medium- term mortality up to more t...
Therapeutic guidelines
Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012
Zhu Peng, Wang YuMing
2013, 29(9): 645-646. DOI: 10.3969/j.issn.1001-5256.2013.09.002
Abstract(4229) PDF (554KB)(1062)
Abstract:
Recommendations of management of adult patients with ascites due to cirrhosis: update 2012
Yang Li, Gao YanHang, Niu JunQi
2013, 29(9): 647-648. DOI: 10.3969/j.issn.1001-5256.2013.09.003
Abstract(3834) PDF (1176KB)(1064)
Abstract:
Paying attention to nutritional management of hepatic encephalopathy in patients with liver cirrhosis:  introduction to ISHEN consensus
Wang MaoRong
2013, 29(9): 649-651. DOI: 10.3969/j.issn.1001-5256.2013.09.004
Abstract:
Recommendation for the standardization of diagnosis and treatment of fatty liver disease
Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association
2013, 29(9): 652-655. DOI: 10.3969/j.issn.1001-5256.2013.09.005
Abstract(3995) PDF (1207KB)(1014)
Abstract:
Chinese guidelines for the management of acute pancreatitis ( Shanghai, 2013)
Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association, Editorial Board of Chinese Journal of Pancreatology, Editorial Board of Chinese Journal of Digestion
2013, 29(9): 656-660. DOI: 10.3969/j.issn.1001-5256.2013.09.006
Abstract(349) PDF (352KB)(1967)
Abstract:
Discussions by experts
Progress in technology and clinical application of non- bioartificial liver support system
Liu XiaoHui, Guo HaiQing, Zhang Jing, Duan ZhongPing
2013, 29(9): 661-665. DOI: 10.3969/j.issn.1001-5256.2013.09.007
Abstract:
Several types of non- bioartificial liver support systems are now widely used in the treatment of severe hepatitis and liver failure, which are life- threatening diseases, but no consensus has been reached regarding its efficacy. The designs and results of high- level studies for evaluating the ther...
Clinical implications of laboratory tests in liver failure and evaluation of new laboratory indices for liver failure
Nie QingHe
2013, 29(9): 666-669. DOI: 10.3969/j.issn.1001-5256.2013.09.008
Abstract:
As liver failure is associated with a complex etiology, complicated clinical types, a wide range of complications, rapid progression, and varied clinical interventions, it is difficult to use a single laboratory index to accurately evaluate the degree of liver function damage and accurately predict ...
Investigation of artificial liver support system combined with stem cell transplantation in treatment of liver failure
He HongLiang, Li JianGuo, Gao ZhiLiang
2013, 29(9): 670-673. DOI: 10.3969/j.issn.1001-5256.2013.09.009
Abstract:
Currently, the main treatment strategies for liver failure include comprehensive medical treatment, artificial liver support system treatment, liver transplantation, and stem cell transplantation. In recent years, major progress has been made in liver failure treatment with artificial liver support ...
Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury
Yu Zheng, Jia JiDong
2013, 29(9): 674-677. DOI: 10.3969/j.issn.1001-5256.2013.09.010
Abstract:
Drug- induced liver injury ( DILI) is the liver injury caused by drugs or their metabolites, which is the common cause of live failure. Currently, there is still a lack of effective predictors and diagnostic and therapeutic methods for DILI. To gives an introduction to DILI from the aspects of risk ...
Original articles_Liver failure and liver support system
Determination of serum M30 and M65 levels and its clinical significance in patients with HBV- related acute- on-chronic liver failure
Zhu Bing, You ShaoLi, Wan ZhiHong, Liu HongLing, Rong YiHui, Zang Hong, Zhang AiMin, Xin ShaoJie
2013, 29(9): 678-680. DOI: 10.3969/j.issn.1001-5256.2013.09.011
Abstract:

Objective To determine the serum M30 and M65 levels in patients with HBV- related acute- on- chronic liver failure ( ACLF) and to investigate their association with this disease. Methods Thirty- one patients with HBV- related ACLF ( 20 cases with response to treatment and 11 cases without response t...

Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta- analysis
Chen XiaoHong, Wu ZongYing, Wang YiPing, Ceng Chao, Pan Tao
2013, 29(9): 681-684. DOI: 10.3969/j.issn.1001-5256.2013.09.012
Abstract:

Objective To evaluate the fatality and adverse event rates of prostaglandin E ( PGE) versus placebo in treating acute liver failure ( ALF) . Methods A search was performed using Cochrane Library, MEDLINE, EMBASE, VIP, CNKI, CBM, and other electronic databases to select randomized controlled trials (...

Preliminary investigation of hybrid bioartificial liver support system in treatment of HBV- related acute- on- chronic liver failure
You ShaoLi, Liu HongLing, Rong YiHui, Zhu Bing, Zang Hong, Liu WanShu, Wan ZhiHong, Mao PanYong, Xin ShaoJie
2013, 29(9): 685-688. DOI: 10.3969/j.issn.1001-5256.2013.09.013
Abstract:

Objective To construct a hybrid bioartificial liver support system and to investigate its safety and efficacy in patients with hepatitis B virus ( HBV) - related acute- on- chronic liver failure ( ACLF) . Methods A hollow fiber bioreactor was constructed using cultured HepG2 cells transfected with h...

Original articles_Liver fibrosis and liver cirrhosis
Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases
Dong XiaoPing
2013, 29(9): 689-691. DOI: 10.3969/j.issn.1001-5256.2013.09.014
Abstract:
Objective To investigate the therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in the treatment of liver fibrosis in chronic hepatitis B ( CHB) . Methods A total of 120 patients with CHB, who were admitted to our hospital from July 2011 to November 2012, were randomly divided int...
Original articles_Biliary diseases
Causes and countermeasures of delayed hemobilia after endoscopic retrograde cholangiopancreatography
Wang JiHeng, Gao Ge, Shi JiuJian
2013, 29(9): 692-694. DOI: 10.3969/j.issn.1001-5256.2013.09.015
Abstract:
Objective To investigate the cause and treatment of delayed hemobilia after endoscopic retrograde cholangiopancreatography ( ERCP) . Methods A retrospective analysis was performed on the complications in 1007 patients after ERCP, and the 7 cases of delayed hemobilia were subjected to analysis of tim...
Original articles_Liver neoplasms
Therapeutic strategy for spontaneous rupture of primary hepatocellular carcinoma: report of 30 cases
Wang YuanXi, Li ZhiWei, Zheng Yu, Chen Jin, Tuo QingHua
2013, 29(9): 695-697. DOI: 10.3969/j.issn.1001-5256.2013.09.016
Abstract:

Objective To investigate the therapeutic strategy for spontaneous rupture of hepatocellular carcinoma ( HCC) . Methods A retrospective analysis was performed on the clinical data of 30 patients with HCC rupture hospitalized at our hospital from January 2008 to December2011, including nine patients t...

Clinical significance of α- fetoprotein in initial diagnosis of primary hepatic cancer
Zhao ChunHua, Zhou WenFeng, Chen WeiHua, Xi Zhen, Zhang ChunMei
2013, 29(9): 698-701. DOI: 10.3969/j.issn.1001-5256.2013.09.017
Abstract:

Objective To investigate the value ofα- fetoprotein ( AFP) in the initial diagnosis of primary hepatic cancer ( PHC) . Methods A retrospective analysis was performed on the initial AFP measurement results and imaging findings of 177 patients who had relatively complete clinical data and had a confir...

Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro
Shen Bo, Nie YuQiang
2013, 29(9): 702-706. DOI: 10.3969/j.issn.1001-5256.2013.09.018
Abstract:

Objective To investigate the inhibitory effect of peroxisome proliferator- activated receptor gamma ( PPARγ) on the development, progression, invasion, and metastasis of liver cancer cells. Methods Hepatocellular carcinoma ( HCC) MHCC97L cells were randomly assigned to be transfected with Ad- PPARγ ...

Case reports
Case of subacute liver failure due to hyperthyroidism
Jing Jing, Luo ShengQiang, Gong Man, Sun YongQiang, Zhang Fan, Zhang Ning, Wu Xin, Liu HongHong
2013, 29(9): 707-708. DOI: 10.3969/j.issn.1001-5256.2013.09.019
Abstract:
Discontinuation of immunosuppressive therapy after liver transplantation: an analysis of one case
Lu: GuoYue, Wang ChuanLei, Sun XiaoDong, Qiu Wei, Du XiaoHong, Zhang Wei, Wang GuangYi
2013, 29(9): 709-710. DOI: 10.3969/j.issn.1001-5256.2013.09.020
Abstract:
Reviews
Research advances in oxidative stress and mitochondrial permeability transition in liver failure
Wang KeFei, Zhu YueKe, Meng QingHua
2013, 29(9): 711-714. DOI: 10.3969/j.issn.1001-5256.2013.09.021
Abstract(2778) PDF (688KB)(618)
Abstract:
Major treatment options for liver failure include clinical medical treatment, and prevention of complications) , artificial liver, liver transplantation, and stem cell transplantation. While these means are known to have produced favorable outcomes, some patients died due to acute and severe onset o...
Clinical utility of hepatic venous pressure gradient for predicting outcome and guiding treatment of cirrhosis and portal hypertension
Cao XunXun, Lu LunGen
2013, 29(9): 715-718. DOI: 10.3969/j.issn.1001-5256.2013.09.022
Abstract(3504) PDF (815KB)(673)
Abstract:
Measurement of the hepatic venous pressure gradient ( HVPG) remains the most commonly used method to assess portal hypertension ( clinically defined as above the normal range of 1- 5 mm Hg) . HVPG measurement can also serve as a predictor of variceal bleeding ( increased risk associated with >10-...
Advances in treatment of primary biliary cirrhosis
Qin Hua, Bai ShiShan
2013, 29(9): 719-721. DOI: 10.3969/j.issn.1001-5256.2013.09.023
Abstract(2482) PDF (589KB)(632)
Abstract:
Primary biliary cirrhosis ( PBC) is a chronic progressive intrahepatic cholestatic disease of unknown cause, and its incidence is increasing year by year. The main therapies for PBC include ursodeoxycholic acid for cholestasis, glucocorticoid or immunosuppressant for abnormal immune response, and sy...